Endo Seeks To Block Generics Of Opana ER That Are Not Crush-Resistant
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo citizen petition asks FDA to determine that the company’s old formulation was withdrawn for safety reasons and to decline approval of ANDAs of that formulation; Purdue Pharma files third OxyContin citizen petition.
You may also be interested in...
Opana ER Should Come Off The US Market, FDA Tells Endo
Agency seeks long-acting opioid’s withdrawal due to evidence the reformulated version increased intravenous abuse; FDA’s action, which Endo is weighing, portends a hard-line stance when it comes to opioid risks under new Commissioner Scott Gottlieb.
Opana ER: Effort To Expand US Label Might Lead To Withdrawal Due To Abuse Problems
FDA advisory committees will weigh concerns that Endo’s reformulated version of oxymorphone extended-release, which does not contain abuse-deterrent labeling, has shifted preferred non-oral route of abuse from intranasal to intravenous, which carries additional safety risks.
Actavis Must Withdraw Opana ER Generic Four Years After Launch
Court finds Actavis infringed two Endo patents, judge to decide whether to award damages. Actavis' non-crush-resistant generic has impeded sales of Endo's newer crush-resistant version.